|
1
|
Starker LF, Akerstrom T, Long WD, et al:
Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73
genes in young patients with clinically non-familial primary
hyperparathyroidism. Horm Cancer. 3:44–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeLellis RA: Parathyroid carcinoma: an
overview. Adv Anat Pathol. 12:53–61. 2005. View Article : Google Scholar
|
|
3
|
Hunt JL, Carty SE, Yim JH, Murphy J and
Barnes L: Allelic loss in parathyroid neoplasia can help
characterize malignancy. Am J Surg Pathol. 29:1049–1055.
2005.PubMed/NCBI
|
|
4
|
Haven CJ, Howell VM, Eilers PH, et al:
Gene expression of parathyroid tumors: molecular subclassification
and identification of the potential malignant phenotype. Cancer
Res. 64:7405–7411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yano S, Sugimoto T, Tsukamoto T, et al:
Decrease in vitamin D receptor and calcium-sensing receptor in
highly proliferative parathyroid adenomas. Eur J Endocrinol.
148:403–411. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arnold A, Shattuck TM, Mallya SM, et al:
Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner
Res. 17(Suppl 2): N30–N36. 2002.PubMed/NCBI
|
|
7
|
Szabo E, Carling T, Hessman O and Rastad
J: Loss of heterozygosity in parathyroid glands of familial
hypercalcemia with hypercalciuria and point mutation in calcium
receptor. J Clin Endocrinol Metab. 87:3961–3965. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valimaki S, Forsberg L, Farnebo LO and
Larsson C: Distinct target regions for chromosome 1p deletions in
parathyroid adenomas and carcinomas. Int J Oncol. 21:727–735.
2002.PubMed/NCBI
|
|
9
|
Cetani F, Pardi E, Giovannetti A, et al:
Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian
kindreds with familial isolated hyperparathyroidism. Clin
Endocrinol (Oxf). 56:457–464. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka C, Uchino S, Noguchi S, et al:
Biallelic inactivation by somatic mutations of the MEN1 gene in
sporadic parathyroid tumors. Cancer Lett. 175:175–179. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cetani F, Pardi E, Borsari S, et al:
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism:
germline and somatic mutations in familial and sporadic parathyroid
tumors. J Clin Endocrinol Metab. 89:5583–5591. 2004. View Article : Google Scholar
|
|
12
|
Hobbs MR, Pole AR, Pidwirny GN, et al:
Hyperpara-thyroidism- jaw tumor syndrome: the HRPT2 locus is within
a 0.7-cM region on chromosome 1q. Am J Hum Genet. 64:518–525. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Howell VM, Haven CJ, Kahnoski K, et al:
HRPT2 mutations are associated with malignancy in sporadic
parathyroid tumours. J Med Genet. 40:657–663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shattuck TM, Valimaki S, Obara T, et al:
Somatic and germ-line mutations of the HRPT2 gene in sporadic
parathyroid carcinoma. N Engl J Med. 349:1722–1729. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moon SD, Park JH, Kim EM, et al: A Novel
IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in
a family with hyperparathyroidism-jaw tumor syndrome. J Clin
Endocrinol Metab. 90:878–883. 2005.
|
|
16
|
Moon S, Kim JH, Shim JY, et al: Analysis
of aberrantly spliced HRPT2 transcripts and the resulting proteins
in HPT-JT syndrome. Mol Genet Metab. 100:365–371. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
18
|
Carpten JD, Robbins CM, Villablanca A, et
al: HRPT2, encoding parafibromin, is mutated in
hyperparathyroidism-jaw tumor syndrome. Nat Genet. 32:676–680.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hewitt KM, Sharma PK, Samowitz W and Hobbs
M: Aberrant methylation of the HRPT2 gene in parathyroid carcinoma.
Ann Otol Rhinol Laryngol. 116:928–933. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang P, Bowl MR, Bender S, et al:
Parafibromin, a component of the human PAF complex, regulates
growth factors and is required for embryonic development and
survival in adult mice. Mol Cell Biol. 28:2930–2940. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmad I, Iwata T and Leung HY: Mechanisms
of FGFR-mediated carcinogenesis. Biochim Biophys Acta.
1823:850–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Moerlooze L, Spencer-Dene B, Revest JM,
Hajihosseini M, Rosewell I and Dickson C: An important role for the
IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in
mesenchymal-epithelial signalling during mouse organogenesis.
Development. 127:483–492. 2000.PubMed/NCBI
|
|
23
|
Turner N and Grose R: Fibroblast growth
factor signalling: from development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haugsten EM, Wiedlocha A, Olsnes S and
Wesche J: Roles of fibroblast growth factor receptors in
carcinogenesis. Mol Cancer Res. 8:1439–1452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwabi-Addo B, Ozen M and Ittmann M: The
role of fibroblast growth factors and their receptors in prostate
cancer. Endocr Relat Cancer. 11:709–724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Freier K, Schwaenen C, Sticht C, et al:
Recurrent FGFR1 amplification and high FGFR1 protein expression in
oral squamous cell carcinoma (OSCC). Oral Oncol. 43:60–66. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meyer KB, Maia AT, O’Reilly M, et al:
Allele-specific up-regulation of FGFR2 increases susceptibility to
breast cancer. PLoS Biol. 6:e1082008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacquemier J, Adelaide J, Parc P, et al:
Expression of the FGFR1 gene in human breast-carcinoma cells. Int J
Cancer. 59:373–378. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murphy T, Darby S, Mathers ME and
Gnanapragasam VJ: Evidence for distinct alterations in the FGF axis
in prostate cancer progression to an aggressive clinical phenotype.
J Pathol. 220:452–460. 2010.PubMed/NCBI
|
|
30
|
Acevedo VD, Gangula RD, Freeman KW, et al:
Inducible FGFR-1 activation leads to irreversible prostate
adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer
Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Armstrong K, Ahmad I, Kalna G, et al:
Upregulated FGFR1 expression is associated with the transition of
hormone-naive to castrate-resistant prostate cancer. Br J Cancer.
105:1362–1369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Urakawa I, Yamazaki Y, Shimada T, et al:
Klotho converts canonical FGF receptor into a specific receptor for
FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Imanishi Y, Nagata Y and Inaba M:
Parathyroid diseases and animal models. Front Endocrinol
(Lausanne). 3:782012.
|
|
34
|
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V,
et al: The parathyroid is a target organ for FGF23 in rats. J Clin
Invest. 117:4003–4008. 2007.PubMed/NCBI
|
|
35
|
Amann T, Bataille F, Spruss T, et al:
Reduced expression of fibroblast growth factor receptor 2IIIb in
hepatocellular carcinoma induces a more aggressive growth. Am J
Pathol. 176:1433–1442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Diez de Medina SG, Chopin D, El Marjou A,
et al: Decreased expression of keratinocyte growth factor receptor
in a subset of human transitional cell bladder carcinomas.
Oncogene. 14:323–330. 1997.PubMed/NCBI
|
|
37
|
Naimi B, Latil A, Fournier G, Mangin P,
Cussenot O and Berthon P: Down-regulation of (IIIb) and (IIIc)
isoforms of fibroblast growth factor receptor 2 (FGFR2) is
associated with malignant progression in human prostate. Prostate.
52:245–252. 2002. View Article : Google Scholar : PubMed/NCBI
|
